Drug reference

Urofollitropin

GnRH Analogue · Infertility treatment

Also known as uFSH, BRAVELLE, MENOPUR, METRODIN, FOLGEST, FOLICULIN

GnRH AnalogueInfertility treatment

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid.

FDA category + note

Mechanism

Urofollitropin is a purified extract of human postmenopausal urine containing follicle-stimulating hormone (FSH) with virtually no luteinizing hormone (LH) activity. FSH binds to specific G protein-coupled receptors on target cells, leading to increased cAMP production. This mechanism stimulates gametogenesis and follicle development in women.

Indications

Infertility in women with proven hypopituitarism or who have not responded to clomifeneSuperovulation treatment for assisted conception (such as in vitro fertilisation)Induction of ovulation in women with polycystic ovarian diseaseImprove chances of obtaining good quality ova for in vitro fertilizationOvarian stimulationIn vitro fertilizationTo improve chances of obtaining good quality ova for in vitro fertilization

Dosing

Adult: Adjusted according to response, by subcutaneous injection or deep intramuscular injection. Usually administered on a daily basis.

Pharmacokinetics

Half-life

2–6 hours

Metabolism

Partly metabolized.

Excretion

Partly metabolized, but mainly excreted unchanged in urine.

Contraindications

Ovarian cysts (not caused by polycystic ovarian syndrome)
Tumours of breast
Tumours of hypothalamus
Tumours of ovaries
Tumours of pituitary
Tumours of uterus
Vaginal bleeding of unknown cause
Acute porphyrias
Hormone dependent malignancies (prostate, breast)

Side effects

Common

Breast tendernessConstipationDiarrhoeaGastrointestinal discomfortHeadacheHot ﬂushIncreased risk of infectionMuscle spasmsNauseaOvarian hyperstimulation syndromePainPelvic painRashVaginal dischargeVaginal haemorrhageVomitingEdemaMood changesAllergic reactions

Serious